Thyroid Incidentaloma on 68Ga-PSMA-11 PET/CT Leading to Detection of Thyroid Metastasis in Metastatic Prostate Carcinoma.
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
01 Mar 2022
01 Mar 2022
Historique:
pubmed:
26
10
2021
medline:
4
2
2022
entrez:
25
10
2021
Statut:
ppublish
Résumé
68Ga-labeled prostate-specific membrane antigen (PSMA)-11 PET/CT has evolved as the noninvasive imaging modality of choice in prostatic adenocarcinoma to detect overexpression of PSMA on prostate cancer cells. Metastasis to the thyroid gland is rarely observed in clinical practice of prostatic adenocarcinoma. Herein, we report the first and rare case of metastatic castration-resistant prostatic adenocarcinoma with thyroid metastasis. The patient demonstrated intensely PSMA-expressing primary prostatic lesion, metastatic lymph nodes, and skeletal lesions, and also mild uptake in thyroid nodule, which on further investigations was established as thyroid metastasis from prostate adenocarcinoma.
Identifiants
pubmed: 34690291
doi: 10.1097/RLU.0000000000003954
pii: 00003072-202203000-00055
doi:
Substances chimiques
Gallium Isotopes
0
Gallium Radioisotopes
0
Oligopeptides
0
gallium 68 PSMA-11
0
Edetic Acid
9G34HU7RV0
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
e300-e301Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest and sources of funding: none declared.
Références
Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin . 2015;65:87–108.
Suman S, Parghane RV, Joshi A, et al. Therapeutic efficacy, prognostic variables and clinical outcome of 177 Lu-PSMA-617 PRLT in progressive mCRPC following multiple lines of treatment: prognostic implications of high FDG uptake on dual tracer PET-CT vis-à-vis Gleason score in such cohort. Br J Radiol . 2019;92:20190380.
Silver DA, Pellicer I, Fair WR, et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res . 1997;3:81–85.
Bostwick DG, Pacelli A, Blute M, et al. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer . 1998;82:2256–2261.
Mannweiler S, Amersdorfer P, Trajanoski S, et al. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res . 2009;15:167–172.
Parghane R, Basu S. Small cell transformation of metastatic prostate adenocarcinoma diagnosed by dual-tracer PET/CT ( 68 Ga-PSMA and 18 F-FDG): potential clinical utility in therapeutic decision making and treatment monitoring. J Nucl Med Technol . 2019;47:85–87.
Ro JY, Guerrieri C, el-Naggar AK, et al. Carcinomas metastatic to follicular adenomas of the thyroid gland. Report of two cases. Arch Pathol Lab Med . 1994;118:551–556.
Escudero RM, Amo FH, Martinez MC, et al. Metastatic prostate cancer on the thyroid cartilage: unusual symptoms of prostatic adenocarcinoma. Case report. Arch Esp Urol . 2011;64:132–135.
Kabeer MA, Lloyd-Davies E, Maskell G, et al. Metastatic prostate cancer masquerading clinically and radiologically as a primary caecal carcinoma. World J Surg Oncol . 2007;5:2.
Albsoul NM, Obeidat FN, Hadidy AM, et al. Isolated multiple bilateral thyroid metastases from prostatic adenocarcinoma: case report and literature review. Endocr Pathol . 2013;24:36–39.